Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Dendritic Cell/Tumor Fusion Vaccine|DRUG: Interleukin-12|DRUG: Interleukin-12
Sponsor: Beth Israel Deaconess Medical Center
Collaborators: Dana-Farber Cancer Institute|Brigham and Women's Hospital|Harvard Medical School (HMS and HSDM)|United States Department of Defense|National Cancer Institute (NCI)